Discussions about creating an integratednpath for drug discovery are becoming allntoo common as researchers and companynexecutives struggle to channel technologicalnadvances toward product developmentngoals. Steven Holtzman, president andnCEO of Infinity Pharmaceuticals, found henwanted to add something new to the dialoguenas the keynote speaker at the recentnBio-IT World Conference in Boston. Tonfocus on the larger context, Holtzmannargued that the real challenge the drug discoverynfield faces is not just integration butnactual value creation. His perspective comesnfrom many years’ experience in the biotechnindustry, including having been MillenniumnPharmaceuticals’ chief business officernand the founder of DNX Corp.
展开▼
